Cramer: Apple Is Th...
Health Care: Drugs
Aastrom Biosciences Inc. (ASTM: NASDAQ)
$1.96 -0.03 | -1.51%
06/01/12 - 03:59 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 0.14 | 0.58 | 0.98 |
| Price to Sales (TTM) | 6,905.55 | 4.62 | 1.42 |
| Price to Book (MRQ) | 0.00 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | -3.50 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -3.20 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -3.00 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -77.80 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -92.90 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | -46.87 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | 6.26 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 1.60 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 1.70 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | n.a. | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -2,612.91 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -2,194.09 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -62.40 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -86.80 | 2.20 | 2.50 |
| Return on Investment (TTM) | 111.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -186.00 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 155.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -339,930.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 0.80 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.40 | 0.40 |
Portfolios with ASTM
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- Contributor10 Cheap Biotech Stocks Tha...
- Usermrtimrx WatchList
- UserMy Folly
- Userbosw119
- Usergellis1360 Portfolio 1
- UserSusu's Stocks
- UserRet2009
- Userspecialinterest
- Userpo boy
Latest ASTM Headlines from TheStreet
- Aastrom Raises Cash To Fund Pivotal Trial 03.09.12 | 12:03 pm
- More Biotech Twitter Mailbag: Orexigen, Affymax, YM Bio, Spectrum & More 02.29.12 | 07:02 am
- Aastrom CEO: Financing Close to Completion 01.18.12 | 08:01 am
- Aastrom Cell Therapy Reverses Effects of Blocked Leg Arteries 11.14.11 | 02:11 pm
- The Next Big Thing In Biotech: Aastrom
11.11.11 | 05:11 am - Biotech Calendar: Key Dates for November 11.01.11 | 10:11 am
- Biotech Calendar: Key Dates for September 08.31.11 | 06:08 am
- 10 Cheap Biotech Stocks That Could Soar 06.28.11 | 07:06 am
- Biotech Stock Mailbag: Live Chat 06.17.11 | 11:06 am
- Biotech Stock Mailbag: Aastrom BioSciences 06.03.11 | 06:06 am
Press Releases for ASTM
Partner Headlines for ASTM
- Follow the Analyst Leader: New Stock Coverage to Watch - Wall St. Cheat Sheet 05.31.12 | 04:05 am
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- Aastrom Biosciences Announces Initiation of Patient Enrollment in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T - Benzinga 02.29.12 | 04:02 pm
- 10 Biotech Stocks Undervalued By Levered Free Cash Flows - Seeking Alpha 12.07.11 | 08:12 am
- Aastrom Bio: Final RESTORE Data Looks Solid - Seeking Alpha 11.15.11 | 09:11 am
- 6 Recently Crushed Stocks With Heavy New Insider Buying - Seeking Alpha 08.14.11 | 09:08 am
- Analyst Interview - International Stem Cell - Analyst Blog - Zacks 07.27.11 | 06:07 am
- Aastrom Files At-the-Market Offering and New Shelf Registration Statement - Benzinga 06.16.11 | 04:06 pm
- Aastrom Biosciences' Trial Meets Safety and Efficacy Endpoints - Seeking Alpha 06.02.11 | 09:06 am
- 6 Speculative Biotech Stocks Smart Money Loves - Seeking Alpha 05.23.11 | 09:05 am
